Hong Kong SAR issues landmark cross-border injunction

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Hong Kong SAR issues landmark cross-border injunction

hong-kong.jpeg

The Hong Kong High Court has handed down an injunction preventing passing off in mainland China, in what has been described as a first-of-its-kind decision

The Hong Kong High Court has issued an order granting a landmark preliminary injunction in favour of US-based nutrition supplement brand ChildLife and restraining passing off in mainland China via e-commerce platforms.

It is the first-ever preliminary injunction issued in Hong Kong SAR concerning passing-off activity in China. The court, in a ruling last Wednesday, October 20, took into consideration torts committed by the defendants outside of Hong Kong SAR and restrained them from passing off in mainland China.

The decision holds major significance as it lays the ground for parties to use Hong Kong SAR as a venue for pursuing infringement and passing off actions against suspected violations taking place in mainland China.

ChildLife, owned by life sciences company Biozeal, took action against an ex-distributor who was operating certain flagship stores in e-commerce platforms through its Hong Kong SAR-registered affiliates and targeting customers in mainland China. This was despite a distribution agreement between the parties being terminated.

According to ChildLife, the ex-distributor had not only refused to transfer the flagship stores to ChildLife after the agreement had ended, but continued to use the brand owner’s marks and device to market its new products.

While deciding jurisdiction, the court noted that the double actionability rule – that an action for an alleged tort committed in a foreign jurisdiction can succeed in a domestic court only if it would be actionable under the laws of both jurisdictions – is still valid in Hong Kong SAR.

The controversial double actionability rule has been abolished in the UK, where it originated, and many other countries worldwide.  

ChildLife was represented by Baker McKenzie. Partner at the firm Andrew Sim said: “This judgment is most significant, as it sets a new precedent for similar cases in the future.”

The defendants have appealed to the Hong Kong Court of Appeal.

more from across site and SHARED ros bottom lb

More from across our site

Ranjna Mehta-Dutt, who moved to Chadha & Chadha after 25 years at Remfry & Sagar, says the firm plans to expand its life sciences practice through targeted recruitment and dedicated teams for bigger clients
The initial contempt of court claim targeted Stobbs and the firm’s client for allegedly interfering with the administration of justice
Acquisition of platform developed by Boehmert & Boehmert lawyer set to create a combined platform for patent drafting and prosecution in Europe
Partner Rob Jacob unveils plans to offer a beginning-to-end trademark service, how to make prosecution profitable, and why IP ‘buy-in’ from the CEO stands the firm in good stead
Sponsored by CAS
CAS provides practical pointers on how intellectual property and R&D teams can work in tandem to unlock tangible benefits and avoid wasted spend
Sponsored by CAS
CAS explores how AI is transforming intellectual property, from inventorship and copyright disputes to new demands on patent attorneys
Sponsored by That.Legal
Gillian Tan of That.Legal discusses a recent decision by the Intellectual Property Office of Singapore and what it reveals about the evidential burden in bad-faith trademark claims
Attorneys at Di Blasi, Parente & Associados share how the protection of trade secrets strengthens innovation by bringing together legal practice, regulatory developments, and established international references
Jin Ooi, who joins as a partner today, said he is excited to offer a ‘rounded’ IP service as the firm deepens its litigation expertise in the UK and Europe
As generics celebrate, practitioners believe innovator companies should brace for an ‘uphill battle’ when trying to prove induced infringement
Gift this article